Bio-Thera Solutions Expands its Collaboration with Biomm for BAT2206 (biosimilar, ustekinumab)

Share this
Bio-Thera Solutions

Bio-Thera Solutions Expands its Collaboration with Biomm for BAT2206 (biosimilar, ustekinumab)


  • Biomm to get an exclusive right to distribute & market BAT2206 in Brazil & will be responsible for filing the dossier in Brazil. Bio-Thera will lead the global development & commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou, China
  • The agreement will use Biomm’s strong local presence, sales & marketing capabilities in Brazil. BAT2206 was approved in Brazil for active PsA in adults as monotx. or in combination with methotrexate; for PsO in patients aged 6yrs.; for adult patients with active CD & UC
  • The P-I study of BAT2206 has been completed & is being studied in the P-III study incl. patients from China & Eastern EU countries. Thera & Biomm collaborated to distribute & market BAT1706, a bevacizumab biosimilar in Brazil

Ref: Businesswire | Image: Bio-Thera Solutions

Related News:- Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions